Results 241 to 250 of about 92,925 (293)

Provider and patient perspectives on the diagnosis and treatment of Alzheimer's disease: A global perspective from the Global Alzheimer's Leadership Series (GoALS)

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Since 2016, the Alzheimer's Association and the Fondation Alzheimer have hosted Global Alzheimer's Leadership Series (GoALS) global think tanks, with world‐leading experts for innovative discussions to advance Alzheimer's disease (AD) research and care.
Philippe Amouyel, Sandrine Andrieu, Angela Bradshaw, Ralph C. Carmona, Magali Dumont, Lea Tenenholz Grinberg, Takeshi Iwatsubo, Oskar Hansson, Clifford R Jack Jr, Gregory A Jicha, Simin Mahinrad, Eric McDade, Catherine J Mummery, Ronald C Petersen, Shelagh Robinson, Julie A. Schneider, Lenny Shellcross, Amanda G Smith, Heather M. Snyder, Beth Tapply, Charlotte Teunissen, Wiesje M. van der Flier, Bruno Vellas, David Wallon, Jeff D Williamson, Donna Wilcock, Maria C. Carrillo   +26 more
wiley   +1 more source

Apolipoprotein variations across APOE genotypes in young and elderly patients with coronary heart disease. [PDF]

Biosci Rep
Zhang Y, Li S, Xu S, Zhao R, Zheng F, Wu J.   +5 more
europepmc   +1 more source

Triazine Thiols Decrease Apolipoprotein B Secretion From Hepatocytes Through Inhibition of Human Carboxylesterase 1. [PDF]

Cell Mol Gastroenterol Hepatol
Blaszkiewicz J, Jiang YL, Liu JT, Martinez-Morant C, Dearth T, van Altena C, Lamprecht MP, Kappler C, Lee MH, Bethard JR, Ball LE, Duncan SA.   +11 more
europepmc   +1 more source

APOC3 Promotes DGAT2-Dependent Triglyceride Accumulation in Hepatocytes During Early Metabolic Dysfunction. [PDF]

Biomolecules
Nguyen TN, Kim HJ, Shim HM, Kang J, Ha EY, Cho H, Park JH.   +6 more
europepmc   +1 more source

Changes in apolipoproteins following ingestion of a beverage delivering <i>β</i>-hydroxybutyrate: results from a randomized placebo-controlled trial. [PDF]

Front Nutr
Liu Y, Kimita W, Bharmal SH, Petrov MS.
europepmc   +1 more source

Epidemiological characteristics of serum small dense low-density lipoprotein cholesterol: From 2017 to 2019 in Chengdu adults, China. [PDF]

Medicine (Baltimore)
Li J, Lv Z, He E, Wang H, Wu L, Wei Y, Quan H, Zhang S.   +7 more
europepmc   +1 more source

Cerebrospinal fluid CEFA composition is enriched in saturated fatty acids and it is altered in Alzheimer's disease. [PDF]

J Lipid Res
Pavanello C, Ossoli A, Comi C, Turri M, Tremolizzo L, Conti E, D'Incecco P, Barbiroli A, Parini P, Mitro N, Caruso D, Sierri G, Re F, Chinello C, Fumagalli C, Magni F, Fernandes K, Calabresi L.   +17 more
europepmc   +1 more source

Decreased Production and Increased Catabolism of Apolipoprotein B-100 in Apolipoprotein B-67/B-100 Heterozygotes

Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
Abstract Apolipoprotein (apo) B-67 is a truncated form of apoB-100 due to deletion of an adenine at cDNA 9327. Heterozygotes have one allele making apoB-100; therefore, plasma apoB levels would be predicted to be at least 50% of normal. However, apoB-67 heterozygotes have total plasma apoB levels that are 24% of normal.
Francine K Welty, Alice H Lichtenstein, P Hugh R Barrett   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Familial defective apolipoprotein B-100: A review

Journal of Clinical Lipidology, 2016
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant genetic disorder of lipid metabolism associated with hyperlipidemia and elevated risk for atherosclerosis. FDB is caused by mutations in APOB reducing the binding affinity between apolipoprotein B-100 and the low-density lipoprotein receptor.
Lars Andersen, André R Miserez
exaly   +5 more sources